Uncle Sam’s Cancer-Fighting Antibodies Up for Licensing Now!
Published Date: 4/3/2026
Notice
Summary
The National Institutes of Health is offering a cool new invention—special human antibodies that can fight certain cancers and autoimmune diseases—for companies to license and develop into treatments. This means businesses can jump on this opportunity to create powerful new medicines using government-backed research. Interested parties should act soon and may need to sign agreements to get full details.
Analyzed Economic Effects
5 provisions identified: 4 benefits, 1 costs, 0 mixed.
NIH Antibodies Available To License
The NIH is offering government-owned human antibodies (HHS Ref. No. E-025-2025; U.S. Provisional Patent 63/787,190 filed April 11, 2025) for companies to license and commercialize. The technology is pre-clinical and includes a potent antibody (NIH58.9) that killed B cells at 0.01 nanomolar, which companies can license under federal technology-transfer rules.
Potential New Treatments For B-Cell Diseases
The NIH antibodies may be developed into treatments for B-cell cancers, organ transplantation uses, and autoimmune conditions such as lupus and multiple sclerosis. The technology is described as pre-clinical and includes an antibody (NIH58.9) that killed B cells at 0.01 nanomolar, and it 'may be used as treatments' or engineered into bispecifics or antibody-drug conjugates.
Confidential Disclosure Agreement Needed
If you want unpublished details about the NIH antibody invention, you must sign a Confidential Disclosure Agreement (CDA) before receiving copies of unpublished information. Contact Benjamin Hurley at the NIAID Technology Transfer Office to request licensing information.
Foreign Patents May Extend Market Coverage
The notice says foreign patent applications are filed on selected inventions to extend market coverage and those foreign rights may also be available for licensing. This can help licensees access non-U.S. markets using government-filed patent protection.
Collaborative Research Opportunities Offered
NIAID is seeking statements of capability or interest from parties for collaborative research to further develop, evaluate, or commercialize the antibody technology (reference E-025-2025). Interested parties should contact the listed Technology Transfer Office representative.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06283 — Prospective Grant of an Exclusive Patent License: Pigment Epithelium-Derived Factor (PEDF) Peptides and Use for Treating Retinal Degeneration
The National Eye Institute plans to give Perpetual Biosciences, Inc. an exclusive license to use special PEDF peptides to treat eye diseases that cause vision loss. This means the company will have the sole right to develop and sell this promising treatment, potentially helping millions with retinal degeneration. If you want to comment or apply for a license, act fast—submissions close April 16, 2026!
2026-05957 — Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding several closed virtual meetings in April 2026 to review and decide on important research grant applications. These meetings affect scientists seeking funding in areas like neuroscience, cancer, and liver disease. No public access is allowed to protect private info and trade secrets, and these reviews help decide where millions in research money will go.
2026-05738 — Submission for OMB Review; 30-Day Comment Request; National Institutes of Health (NIH) Loan Repayment Programs, (Office of the Director)
The NIH is asking for a 30-day public comment on extending its Loan Repayment Programs that help doctors and scientists pay off their student loans while they do important health research. This extension keeps the program running smoothly with no big changes, and comments are due by April 23, 2026. If you’re a researcher with student loans, this program could save you money while you help improve health!
2026-05673 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings on April 17, 2026, to review and evaluate important grant applications in health and science fields. These meetings protect private info and trade secrets while deciding who gets funding. Researchers and organizations applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
2026-05672 — National Institute on Deafness and Other Communication Disorders; Notice of Closed Meetings
The National Institute on Deafness and Other Communication Disorders is holding two closed meetings in late April and early May 2026 to review grant applications and evaluate researchers’ qualifications. These meetings affect scientists seeking funding and help ensure top-notch research gets supported. No public access means privacy is protected, and the process keeps the money flowing to the best projects on time.
2026-05527 — Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a cool new gene-editing invention that can fix a rare genetic disease called ROSAH syndrome, which causes vision loss and other problems. Companies can license this technology to develop treatments that might restore vision and improve lives. Interested parties should act soon and be ready to sign a confidentiality agreement to get all the details.
Previous / Next Documents
Previous: 2026-06500 — Medicare and Medicaid Programs; Approval of Application by the Accreditation Commission for Health Care Inc. (ACHC) for Continued CMS-Approval of its Hospice Accreditation Program
The Accreditation Commission for Health Care Inc. (ACHC) just got the green light to keep accrediting hospice programs that want to work with Medicare and Medicaid. This approval lasts from November 27, 2025, to November 27, 2031, letting hospices skip some state inspections if they meet ACHC’s standards. This keeps things smooth and helps hospices focus on caring for patients without extra paperwork or delays.
Next: 2026-06502 — Evaluation of Pennsylvania Coastal Management Program; Notice of Public Meeting; Request for Comments
NOAA is checking how well Pennsylvania’s Coastal Management Program is working and wants your thoughts! They’re hosting a virtual meeting on May 19, 2026, where you can speak up, and you can also send written comments by May 29. This is a chance for anyone who cares about Pennsylvania’s coast to help shape future plans—no money changes yet, just your voice making waves!
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in